REPLIGEN CORPORATION

Company Information

Company Name
REPLIGEN CORPORATION
Address
REPLIGEN CORPORATION
41 SEYON ST, STE 100
WALTHAM, MA, 02453
Phone
1 781-250-0111
URL
n/a
DUNS
n/a
Number of Employees
n/a

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$576,683.00
8
SBIR Phase II
$1,228,999.00
2
Chart code to be here

Award List

  1. LIGNINOLYTIC ENZYMES APPLIED TO KRAFT LIGNIN AND LIGNOSULFONATE UTILIZATION

    Amount: $479,000.00

    LIGNIN, A COMPLEX ORGANIC POLYMER AND ONE OF THE EARTH'S MOST ABUNDANT MOLECULES, IS NOW A LOW-VALUE BY-PRODUCT OF WOOD PULP PROCESSING. THE MAJOR LIGNIN BY-PRODUCTS, KRAFT LIGNIN, AND LIGNOSULFONATES ...

    SBIR Phase II 1986 Department of Energy
  2. GENERATION OF PF4 POLYETHYLENE GLYCOL CONJUGATES

    Amount: $27,274.00

    ANGIOGENESIS IS A COMPLEX PROCESS INVOLVING THE PROLIFERATION, MIGRATION, AND PRECISE THREE DIMENSIONAL ALIGNMENT OF ENDOTHELIAL CELLS. A WIDE RANGE OF DISEASE PROCESSES INCLUDING SOLID TUMOR GROWTH, ...

    SBIR Phase I 1991 Department of Health and Human Services
  3. ANTIBODY HETEROCONJUGATES FOR TREATMENT OF SIV INFECTION

    Amount: $49,984.00

    THE GOAL OF THIS PROJECT IS TO GENERATE AND CHARACTERIZE A BISPECIFIC HETEROCONJUGATE ANTIBODY CAPABLE OF INDUCING THE CYTOLYSIS OF SIV-INFECTED CELLS. THE APPROACH IN PHASE I STUDY WILL ENTAIL CONJUG ...

    SBIR Phase I 1991 Department of Health and Human Services
  4. Development of Chemokines for Myeloprotection

    Amount: $99,998.00

    We will develop a myelostatic agent to protect human hematopoietic precursor cells from the destrucchemotherapeutic agents currently used in the treatment of tumors. We propose that protection of prei ...

    SBIR Phase I 1995 Department of Health and Human Services
  5. Development of Chemokines for Myeloprotection

    Amount: $749,999.00

    We will develop a myelostatic agent to protect human hematopoietic precursor cells from the destrucchemotherapeutic agents currently used in the treatment of tumors. We propose that protection of prei ...

    SBIR Phase II 1998 Department of Health and Human Services
  6. Development of a Heparinoid Affinity Matrix by Combinatorial Chemistry

    Amount: $99,906.00

    N/A

    SBIR Phase I 1999 National Science Foundation
  7. HEPARANASE INHIBITORS FOR USE IN METASTATIC DISEASES

    Amount: $99,660.00

    Not Available Oman Moments, Inc. will conduct a Phase 1 trade study to determine the best approach for providing both day and night imaging of ground targets from a supersonic missile. The objective ...

    SBIR Phase I 1999 Department of Health and Human Services
  8. IMPROVED SECRETIN ANALOGS FOR THE TREATMENT OF AUTISM

    Amount: $100,000.00

    Non invasive MRI evaluation of the carotid artery wall lumen and blood flow patterns is hampered by the lack of a comprehensive and anatomically correct commercially available flow phantom. The objec ...

    SBIR Phase I 2002 Department of Health and Human Services
  9. LIGNINOLYTIC ENZYMES APPLIED TO KRAFT LIGNIN AND LIGNOSULFONATE UTILIZATION

    Amount: $50,000.00

    N/A

    SBIR Phase I 1985 Department of Energy
  10. SUPPOSITORIES FOR RAPID ANTI-EPILEPTIC DIAZEPAM DELIVERY

    Amount: $49,861.00

    N/A

    SBIR Phase I 1991 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government